^
    3d
    Tubulin-Based Microtentacles Aid in Heterotypic Clustering of Neutrophil-Differentiated HL-60 Cells and Breast Tumor Cells. (PubMed, Adv Sci (Weinh))
    Neutrophil McTNs aid in cluster formation, migration, and reattachment, which are suppressed with the tubulin-depolymerizing agent, Vinorelbine...CTC-neutrophil clusters have higher metastatic efficiency, and by demonstrating that neutrophils form McTNs, a new possible mechanism for how neutrophils interact with tumor cells is revealed. These findings further support the idea that developing cluster-disrupting therapies can provide a new targeted strategy to reduce the metastatic potential of cancer cells.
    Journal • Tumor cell
    |
    VIM (Vimentin)
    |
    vinorelbine tartrate
    7d
    An endoplasmic reticulum stress related signature for clinically predicting prognosis of breast cancer patients. (PubMed, Hum Mol Genet)
    Our ER stress model performed a valuable prediction on breast cancer patients.
    Journal
    |
    SERPINA1 (Serpin Family A Member 1)
    |
    cisplatin • docetaxel • vinorelbine tartrate
    10d
    OptiTROP-Breast01: SKB264 Injection Vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=254, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Trial completion date: Dec 2024 --> Mar 2025
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 expression • PGR negative • HER-2 negative + HR positive + BRCA mutation
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • sacituzumab tirumotecan (MK-2870)
    17d
    ARST1431: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (clinicaltrials.gov)
    P3, N=325, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    FOXO1 (Forkhead box O1) • PAX3 (Paired Box 3) • PAX7 (Paired Box 7)
    |
    cyclophosphamide • irinotecan • Torisel (temsirolimus) • vincristine • vinorelbine tartrate • dactinomycin
    18d
    Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer. (PubMed, Int J Cancer)
    Most interestingly, the triplet treatment exhibited a safer toxicological profile than the doublet (vinorelbine plus carboplatin) currently applied in the clinical practice. Altogether, these preclinical data support the possibility of repurposing pirfenidone in combination with vinorelbine or with vinorelbine plus carboplatin for NSCLC perioperative treatment, improving therapeutic efficacy while reducing toxicity.
    Preclinical • Journal
    |
    VIM (Vimentin)
    |
    VIM expression
    |
    carboplatin • vinorelbine tartrate
    18d
    Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=257, Recruiting, Memorial Sloan Kettering Cancer Center | N=69 --> 257
    Enrollment change
    |
    Keytruda (pembrolizumab) • gemcitabine • vinorelbine tartrate
    23d
    Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=168, Recruiting, Shanghai Yizhong Pharmaceutical Co., Ltd. | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    gemcitabine • paclitaxel • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate
    24d
    Evolutionary Therapy for Rhabdomyosarcoma (clinicaltrials.gov)
    P2, N=28, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2027 --> Aug 2027 | Trial primary completion date: Dec 2026 --> Aug 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    FOXO1 (Forkhead box O1)
    |
    doxorubicin hydrochloride • cyclophosphamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin • Navelbine oral (vinorelbine tartrate oral)
    25d
    ZWI-ZW25-101: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers (clinicaltrials.gov)
    P1, N=279, Completed, Jazz Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • ALK-ROS1 fusion • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
    |
    paclitaxel • capecitabine • Tukysa (tucatinib) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)
    1m
    CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Eli Lilly and Company | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    cyclophosphamide • Cyramza (ramucirumab) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    1m
    TROPION-Lung12: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (clinicaltrials.gov)
    P3, N=660, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Circulating tumor DNA
    |
    cisplatin • carboplatin • pemetrexed • etoposide IV • vinorelbine tartrate • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936)
    1m
    SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Peking University Shenzhen Hospital
    New P2 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • gemcitabine • Rozlytrek (entrectinib) • imatinib • 5-fluorouracil • Tyvyt (sintilimab) • Alecensa (alectinib) • Nerlynx (neratinib) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Irene (pyrotinib) • Balversa (erdafitinib) • albumin-bound paclitaxel • irinotecan • Orpathys (savolitinib) • epirubicin • vinorelbine tartrate • Partruvix (pamiparib) • Epkinly (epcoritamab-bysp) • Hetronifly (serplulimab) • Enweida (envafolimab) • Vumon (teniposide) • Ariely (adebrelimab)
    1m
    Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial. (PubMed, J Transl Int Med)
    The incidence of adverse events (AEs) was generally consistent across all levels. There were slight differences in the mean Cmax, Cmin, AUCtau and Cav between the three-week dosing group and the single-week dosing group, and the mean steady-state concentrations of Cav were comparable; however, there were no differences in efficacy, safety or immunogenicity between the two groups.
    P2 data • Journal • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    vinorelbine tartrate • Cipterbin (inetetamab)
    1m
    AZALEA: Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, European Institute of Oncology
    New P2 trial • Metastases
    |
    Tecentriq (atezolizumab) • cyclophosphamide • vinorelbine tartrate
    1m
    A Multicentre Real-World Study to Assess the Efficacy and Safety of Ametinib Mesylate Tablets in Combination with Vinorelbine Tartrate Soft Capsules Against Ametinib Monotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR-Sensitive Mutations (ChiCTR2400090618)
    P4, N=514, Not yet recruiting, Anhui Chest Hospital; Anhui Chest Hospital
    New P4 trial • Combination therapy • Real-world evidence • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    vincristine • vinorelbine tartrate
    1m
    A single-arm, single-center clinical study of chidamide in combination with vinorelbine and capecitabine in the treatment of HER2-negative advanced breast cancer (ChiCTR2400090102)
    P2, N=26, Not yet recruiting, ChongQing university cancer hospital; ChongQing university cancer hospital
    New P2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • vinorelbine tartrate • Epidaza (chidamide)
    2ms
    Peptide-Conjugated Vascular Endothelial Extracellular Vesicles Encapsulating Vinorelbine for Lung Cancer Targeted Therapeutics. (PubMed, Nanomaterials (Basel))
    Further, we examined the binding affinity of ABCB1, encoding P-glycoprotein, which plays a crucial role in chemoresistance via the efflux of the drug. Our results indicate that GE11-HUVEC-EVs-Vin effectively showed tumoricidal effects against cell and mouse models of lung cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    EGFR overexpression
    |
    vinorelbine tartrate
    2ms
    NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target. (PubMed, Int J Biol Sci)
    In this study, by conducting bioinformatics analyses as well as in vitro and in vivo experiments, we identified that NUSAP1 was significantly upregulated in LUAD, with a notable correlation with poorer overall survival, higher scores for immunogenicity and immune infiltration, as well as increased sensitivity to conventional chemotherapeutic drugs such as paclitaxel, docetaxel and vinorelbine in LUAD. Furthermore, we identified entinostat as a novel inhibitor of NUSAP1. Pharmacological targeting ERβ/NUSAP1 axis with fulvestrant (ERβ antagonist) or entinostat (novel NUSAP1 inhibitor) significantly reduced LUAD growth both in vitro and in vivo, which may represent effective alternative therapeutic strategies for patients with LUAD.
    Journal
    |
    NUSAP1 (Nucleolar and Spindle Associated Protein 1)
    |
    NUSAP1 overexpression
    |
    paclitaxel • docetaxel • fulvestrant • vinorelbine tartrate • Jingzhuda (entinostat)
    2ms
    Neutrophil-related Signature Characterizes Immune Landscape and Predicts Prognosis of Invasive Breast Cancer. (PubMed, Biochem Genet)
    In addition, patients with low NRGs scores were considerably more sensitive to vinorelbine, cyclophosphamide, epirubicin, gemcitabine, paclitaxel, 5-fluorouracil, docetaxel, and cisplatin. Moreover, qRT-PCR results confirmed that LEF1 had a higher expression level in tumor samples compared to normal samples, whereas NRG1 and STX11 exhibited lower expression levels in tumor samples than in normal samples. These results suggest that NRGs might be utilized as biomarkers to predict the prognosis of individuals with IBC, thereby paving the way for the creation of customized therapies for IBC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NRG1 (Neuregulin 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    cisplatin • gemcitabine • paclitaxel • docetaxel • 5-fluorouracil • cyclophosphamide • epirubicin • vinorelbine tartrate
    2ms
    DUBHE-L-304: A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. (clinicaltrials.gov)
    P3, N=632, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Oct 2031 --> May 2029 | Trial primary completion date: Oct 2028 --> Aug 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • vinorelbine tartrate • Qibeian (iparomlimab/tuvonralimab)
    2ms
    FOXN3-AS1: A Candidate Prognostic Marker and Epigenetic Target with Immunotherapeutic Implications in Acute Myeloid Leukemia. (PubMed, Curr Med Chem)
    Our candidate approach identifies FOXN3-AS1 as a prognostic indicator of survival in AML with a potential immune-related role. The preliminary observations we made on FOXN3-AS1/DNMT1 crosstalk warrant more in-depth invested immunotherapeutic approaches in AML.
    Journal • IO biomarker
    |
    GLI2 (GLI Family Zinc Finger 2)
    |
    cisplatin • Tagrisso (osimertinib) • temozolomide • Jakafi (ruxolitinib) • dactolisib (RTB101) • vinorelbine tartrate • ulixertinib (BVD-523) • sapitinib (AZD8931)
    2ms
    Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1100, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New P3 trial • Surgery
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • pemetrexed • vinorelbine tartrate
    3ms
    A Phase II Clinical Study on Apatinib Plus Vinorelbine in Refractory HER2-Negative Breast Cancer and its Metabolic Implications of Drug Resistance. (PubMed, Curr Cancer Drug Targets)
    Apatinib combined with vinorelbine is effective and safe in patients with locally advanced or metastatic refractory HER2-negative breast cancer. The findings of this study con-tribute to a better understanding of the metabolic effect of apatinib and vinorelbine therapy.
    Clinical • P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    AiTan (rivoceranib) • vinorelbine tartrate
    3ms
    A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (clinicaltrials.gov)
    P4, N=130, Completed, German Breast Group | Recruiting --> Completed | Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Mar 2023 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Ibrance (palbociclib) • paclitaxel • tamoxifen • capecitabine • fulvestrant • letrozole • epirubicin • vinorelbine tartrate • exemestane
    3ms
    Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=69, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • gemcitabine • vinorelbine tartrate
    3ms
    ORIENTA: Organoid-based Functional Precision Therapy for Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=252, Recruiting, Guangdong Provincial People's Hospital | Initiation date: Jan 2024 --> Sep 2024
    Trial initiation date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • ER positive + PGR positive • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)
    3ms
    CAMPFIRE: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (clinicaltrials.gov)
    P2, N=105, Recruiting, Eli Lilly and Company | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    gemcitabine • docetaxel • temozolomide • Verzenio (abemaciclib) • cyclophosphamide • Cyramza (ramucirumab) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    3ms
    FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=350, Recruiting, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate
    3ms
    Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. (PubMed, J Clin Oncol)
    Patients receiving Dato-DXd had statistically significant and clinically meaningful improvement in PFS and a favorable and manageable safety profile, compared with ICC. Results support Dato-DXd as a novel treatment option for patients with inoperable/metastatic HR+/HER2‒ breast cancer who have received one to two previous lines of chemotherapy in this setting.
    Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • datopotamab deruxtecan (DS-1062a)
    4ms
    Overcoming Breast Cancer Drug Resistance: A Novel Approach Using siRNA-Mediated P-glycoprotein Downregulation to Enhance Vinorelbine Efficacy. (PubMed, Adv Pharm Bull)
    The results of the present study indicate that the concurrent use of siRNA and vinorelbine holds substantial promise as a therapeutic approach to overcome ABCB1-mediated multidrug resistance (MDR) in breast cancer. It is necessary to conduct comprehensive clinical trials to determine the true effectiveness of this combination therapy.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    vinorelbine tartrate
    4ms
    LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients (clinicaltrials.gov)
    P=N/A, N=29, Not yet recruiting, University of Illinois at Chicago
    New trial
    |
    gemcitabine • paclitaxel • docetaxel • pemetrexed • vinorelbine tartrate
    4ms
    Stage I and II nonsmall cell lung cancer treatment options. (PubMed, Breathe (Sheff))
    There is evidence that neoadjuvant treatment (immunotherapy with nivolumab and chemotherapy for stage IB and II) optimises outcomes. Adjuvant chemotherapy with a platinum-based doublet (typically cisplatin+vinorelbine) should be offered for resected stage IIB tumours and considered for resected IIA tumours. Adjuvant pembrolizumab is used for stage IB-IIIA following resection and adjuvant platinum-based chemotherapy. Osimertinib may be used for resected stage IB to IIIA cancers which have relevant mutations (epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution). There are no fixed guidelines for follow-up, but most centres recommend 6-monthly CT scanning for the first 2-3 years after definitive treatment, followed by annual scans.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Tagrisso (osimertinib) • vinorelbine tartrate
    4ms
    Imatinib Therapy of Chronic Myeloid Leukemia Significantly Reduces Carnitine Cell Intake, Resulting in Adverse Events. (PubMed, Mol Metab)
    This preclinical experimental study revealed detrimental effect of imatinib on carnitine-mediated energy metabolism of muscle cells providing a possible molecular background of the frequently occurred side effects during imatinib therapy such as fatigue, muscle pain and cramps.
    Journal • Adverse events
    |
    ABL1 (ABL proto-oncogene 1)
    |
    imatinib • vinorelbine tartrate
    4ms
    TROPION-Lung12: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (clinicaltrials.gov)
    P3, N=660, Not yet recruiting, AstraZeneca
    New P3 trial • Combination therapy • Circulating tumor DNA
    |
    cisplatin • carboplatin • pemetrexed • etoposide IV • vinorelbine tartrate • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936)
    4ms
    Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial (clinicaltrials.gov)
    P2, N=240, Recruiting, Henan Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    capecitabine • albumin-bound paclitaxel • fulvestrant • vinorelbine tartrate
    4ms
    A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, AstraZeneca | Trial primary completion date: Aug 2025 --> Jul 2024
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • datopotamab deruxtecan (DS-1062a)
    4ms
    ZWI-ZW25-101: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers (clinicaltrials.gov)
    P1, N=279, Active, not recruiting, Jazz Pharmaceuticals | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    paclitaxel • capecitabine • Tukysa (tucatinib) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)
    4ms
    Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial. (PubMed, Lancet Oncol)
    A thoracic radiotherapy boost, based on interim [18F]FDG-PET, led to a meaningful local control rate with no difference in adverse events between the two groups in organs at risk, in contrast with previous attempts at thoracic radiation intensification, warranting a randomised phase 3 evaluation of such [18F]FDG-PET-guided radiotherapy dose adaptation in patients with stage III NSCLC.
    P2 data • Journal • FDG PET
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    cisplatin • carboplatin • paclitaxel • vinorelbine tartrate
    5ms
    Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer After Trastuzumab Failure (PROVE): A Prospective Phase 2 Study. (PubMed, Cancer Res Treat)
    The combination of pyrotinib and capecitabine has showed efficacy in these patients. There were no grade 4/5 AEs. Pyrotinib combined with metronomic vinorelbine showed promising efficacy and an acceptable safety profile in HER2-positive advanced breast cancer patients after trastuzumab failure.
    P2 data • Journal • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • capecitabine • Irene (pyrotinib) • vinorelbine tartrate
    5ms
    JZP598-303: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer (clinicaltrials.gov)
    P3, N=550, Recruiting, Jazz Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Apr 2031 --> Nov 2031 | Trial primary completion date: Apr 2031 --> Sep 2028
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)
    5ms
    Adaptive Therapy for Post-Second-Line Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=10, Recruiting, Sun Yat-sen University
    New P2 trial • Metastases
    |
    gemcitabine • Halaven (eribulin mesylate) • vinorelbine tartrate
    5ms
    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)
    P3, N=686, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • sacituzumab tirumotecan (MK-2870) • Tivdak (tisotumab vedotin-tftv)